Bio-Path Holdings (BPTH) plans AML trial restart and crypto treasury
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Bio-Path Holdings, Inc. reported unregistered equity sales under its Tier 1 Regulation A program, selling 466,100 and 489,200 common shares for net proceeds of $13,983 and $14,676, with capacity to raise an additional $571,341. The board approved a new Series B Preferred stock class with 5,000,000 authorized shares, each convertible into 1,000 common shares, voting on an as-converted basis and carrying a par value of $0.01.
The company describes a strategic turnaround that may include restarting drug trials, monetizing its oncology intellectual property, and building a digital asset treasury. MD Anderson Cancer Center agreed to restart Phase 2 AML trials if Bio-Path pays past-due balances of $292,264.21 and $63,286.55. Bio-Path opened a Coinbase account and may allocate up to 50% of capital raised to crypto opportunities, acquired a majority stake in Himalaya Technologies, Inc. via Series B Preferred issuances valued at $670,260, and issued additional Series B shares to its CEO for software. It added altFINS founder Richard Fetyko to its advisory board and signed an LOI contemplating 2,500,000 common share equivalents and an option to buy up to 22% of altFINS for two million euros; multiple initiatives remain subject to payments, definitive agreements, and successful capital raising.
Positive
- None.
Negative
- None.
8-K Event Classification
4 items: 3.02, 5.03, 7.1, 8.1
4 items
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 7.1
Item 7.1
Item 8.1
Item 8.1
Key Figures
Reg A sale 1: 466,100 shares; $13,983 net proceeds
Reg A sale 2: 489,200 shares; $14,676 net proceeds
Remaining Reg A capacity: $571,341
+5 more
8 metrics
Reg A sale 1
466,100 shares; $13,983 net proceeds
Common shares sold on April 30, 2026 under Tier 1 Regulation A
Reg A sale 2
489,200 shares; $14,676 net proceeds
Common shares sold on May 13, 2026 under Tier 1 Regulation A
Remaining Reg A capacity
$571,341
Additional capital the company states it can raise under the qualified offering
Series B Preferred authorized
5,000,000 shares
New Series B Preferred stock class approved July 14, 2026
Series B conversion ratio
1,000 common shares per Series B share
Each Series B Preferred share is convertible into 1,000 common shares
MD Anderson balance BP1001-201-AML
$292,264.21
Amount Bio-Path must pay for MD Anderson to restart BP1001-201-AML Phase 2 trial
MD Anderson balance BP1002-201-AML
$63,286.55
Amount Bio-Path must pay for MD Anderson to restart BP1002-201-AML Phase 2 trial
Himalaya Technologies transaction value
$670,260
Value assigned to Series B Preferred shares issued to acquire majority of HMLA
Key Terms
Tier 1 Regulation A offering, Series B Preferred stock, Regulation FD Disclosure, Digital Asset Treasury 2.0, +1 more
5 terms
Tier 1 Regulation A offering regulatory
"On April 30, 2026, under our qualified Tier 1 Regulation A offering, we sold 466,100 common shares"
Series B Preferred stock financial
"approved the creation of new class of Series B Preferred stock with five million (5,000,000) authorized shares"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Regulation FD Disclosure regulatory
"Item 7.1 Regulation FD Disclosure We are in the midst of a strategic turnaround"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
Digital Asset Treasury 2.0 financial
"We intend to add altFINS’ AI driven capabilities to our recently announced Digital Asset Treasury 2.0 (DAT 2.0)"
Qualified Opportunity Zones financial
"Strategically focused on asset classes within federally designated Qualified Opportunity Zones, the firm operates"
FAQ
What equity sales did Bio-Path Holdings (BPTH) disclose under its Tier 1 Regulation A offering?
Bio-Path sold 466,100 and 489,200 common shares, generating net proceeds of $13,983 and $14,676. The company states it can still raise up to $571,341 under the same qualified offering, though there are no assurances this capacity will be used.
How is Bio-Path Holdings (BPTH) structuring its new Series B Preferred stock?
The board approved 5,000,000 authorized Series B Preferred shares, each convertible into 1,000 common shares. Series B votes on an as-converted basis, pays no dividends, and carries no liquidation amount above its $0.01 par value according to the disclosure.
What agreement did BPTH reach with MD Anderson regarding its AML Phase 2 trials?
MD Anderson agreed to restart Bio-Path’s Phase 2 AML trials if it is brought current on past-due balances of $292,264.21 for BP1001-201-AML and $63,286.55 for BP1002-201-AML. Bio-Path believes the BP1001 trial will remain randomized and plans to seek outside funding and grants.
What crypto and digital asset strategy did Bio-Path Holdings (BPTH) outline?
Bio-Path opened a business account with Coinbase to manage an AI-driven digital asset treasury targeting L1, L2, and altcoins. It states an intention to allocate up to 50% of capital raised to crypto opportunities and to enhance these efforts with altFINS’ AI capabilities via a planned partnership.
How did Bio-Path Holdings (BPTH) gain control of Himalaya Technologies (HMLA)?
Bio-Path issued 22,342 Series B Preferred shares, valued at $670,260, in exchange for Himalaya Technologies’ preferred securities, making HMLA a majority owned subsidiary. HMLA operates Mophoe.com, a crypto-focused social and trading platform currently under development, according to the disclosure.
What are the key terms of BPTH’s LOI and advisory relationship with altFINS?
Bio-Path added altFINS CEO Richard Fetyko to its advisory board, granting up to 300,000 options, including initial warrants for 100,000 shares at $0.03. An LOI contemplates issuing 2,500,000 common share equivalents and granting an option to buy up to 22% of altFINS for two million euros.